Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0344307 (
analgesia
)
28,200
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
An 18-month-old Lurcher was anaesthetized for surgical ligation of a patent ductus arteriosus using a target-controlled infusion (TCI) of propofol and a variable rate infusion of remifentanil. Before anaesthesia, radiographic and echocardiographic examination indicated that the dog had left-sided congestive heart failure and impaired left ventricular systolic function.
Ramipril
and furosemide were administered pre-operatively. Following pre-anaesthetic medication with morphine, 0.5 mg kg(-1), by intramuscular injection, and pre-oxygenation, remifentanil was infused for 5 minutes at 0.2 microg kg(-1) minute(-1), followed by induction of anaesthesia using intravenous propofol administered by TCI, set at a target concentration of 3.5 microg mL(-1) of propofol in blood. Tracheal intubation was performed and 100% oxygen delivered through a non-rebreathing (Bain) system and then a circle system in the operating theatre. Anaesthesia was maintained with propofol and remifentanil, adjusted according to clinical requirements. Peri-operative
analgesia
consisted of intercostal bupivacaine nerve block, with meloxicam, morphine and remifentanil.
...
PMID:Target-controlled infusion of propofol combined with variable rate infusion of remifentanil for anaesthesia of a dog with patent ductus arteriosus. 1768 20
The angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are a well known entity and have been used in therapeutics for various indications like hypertension, myocardial infarction and CHF. However, there is a renewed interest in these compounds in terms of their effects on pain perception in animals as well as in human beings. They have yielded contradictory results, showing hyperalgesia in some studies but
analgesia
in others. Hence this study was undertaken to evaluate the effect of
Ramipril
(an ACE-I) and Losartan (an ARB) on pain perception in human volunteers using cola caps and handcuff of sphygmomanometer. A total of 30 healthy, normotensive individuals with no previous history of intake of analgesics during or 4 weeks prior to the study were selected after an informed consent. The first group received a single dose of placebo, the second group received
Ramipril
(2.5 mg) & the third group received Losartan (50 mg). Pain perception threshold (the point at which an individual first experiences pain) and the maximum tolerated pain were assessed using the above method. The control group showed no significant changes in pain threshold, but the group receiving either
Ramipril
or Losartan showed a decline in threshold for maximum tolerated pain. Only
Ramipril
and not Losartan decreased the pain perception threshold. Our study revealed that single dose treatment of healthy volunteers with
Ramipril
and Losartan may cause algesia as early as after ingestion of the first dose and further studies are needed to study their long term effects on pain perception.
...
PMID:Modulation of pain perception by ramipril and losartan in human volunteers. 1883 57